Sept 12 (Askume) – Avadel Pharmaceuticals (AVDL.O) said in a regulatory filing on Thursday that the U.S. Food and Drug Administration is still reviewing its sleep disorder drug for use in pediatric patients ages 7 and older.

    Health regulators are expected to make a decision by Sept. 7. Awadr did not provide details about the date of the new operation.